Last update 29 Nov 2024

Insulin degludec/Insulin aspart (Huisheng Pharm)

Overview

Basic Info

Drug Type
Biosimilar, Hormone
Synonyms
Insulin Degludec / Insulin Aspart Biosimilar (Jilin Huisheng Biological Pharmaceutical Co., Ltd.), 德谷门冬双胰岛素生物类似药（Jilin Huisheng Biological Pharmaceutical Co., Ltd.）, 惠優加
Target
INSR
Mechanism
INSR agonists(Insulin receptor agonists)
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
Diabetes Mellitus, Type 2
Inactive Indication-
Originator Organization
Jilin Huisheng Biological Pharmaceutical Co., Ltd.
Active Organization
Jilin Huisheng Biological Pharmaceutical Co., Ltd.
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
CN (30 Jul 2024),
Diabetes Mellitus, Type 2
Regulation-
Login to view timeline

Related

2
Clinical Trials associated with Insulin degludec/Insulin aspart (Huisheng Pharm)
CTR20212490 / Active, not recruitingPhase 3
德谷门冬双胰岛素注射液治疗2型糖尿病的有效性和安全性的多中心、随机、开放、平行、阳性对照的III期研究
[Translation] A multicenter, randomized, open, parallel, positive-controlled phase III study on the efficacy and safety of degludec and insulin aspart injection in the treatment of type 2 diabetes
CTR20213361 / Not yet recruitingPhase 1
德谷门冬双胰岛素注射液与诺和佳®/RYZODEG®在中国健康受试者中的药代动力学及安全性的随机、开放、单剂量、两周期、交叉的I期临床研究
[Translation] A randomized, open-label, single-dose, two-period, crossover phase I clinical study on the pharmacokinetics and safety of degludec and insulin aspart injection versus Tresiba®/RYZODEG® in healthy Chinese subjects
100 Clinical Results associated with Insulin degludec/Insulin aspart (Huisheng Pharm)
Login to view more data
100 Translational Medicine associated with Insulin degludec/Insulin aspart (Huisheng Pharm)
Login to view more data
100 Patents (Medical) associated with Insulin degludec/Insulin aspart (Huisheng Pharm)
Login to view more data
100 Deals associated with Insulin degludec/Insulin aspart (Huisheng Pharm)
Login to view more data

R&D Status

10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Diabetes Mellitus, Type 2
CN
Jilin Huisheng Biological Pharmaceutical Co., Ltd.
30 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free